Virtual screening for plant PARP inhibitors – what can be learned from human PARP inhibitors?

Virtual screening for plant PARP inhibitors – what can be learned from human PARP inhibitors?

Bibliographic Details
Main Authors:	Heym Peter-Paul, Brandt Wolfgang, Wessjohann Ludger A, Niclas Hans-Joachim
Format:	Article
Language:	English
Published:	BMC 2012-05-01
Series:	Journal of Cheminformatics

Similar Items

Identification of PARP12 Inhibitors By Virtual Screening and Molecular Dynamics Simulations
by: Tahani M. Almeleebia, et al.
Published: (2022-08-01)

Interactions of PARP1 Inhibitors with PARP1-Nucleosome Complexes
by: Natalya Maluchenko, et al.
Published: (2022-10-01)

A PARP1-related prognostic signature constructing and PARP-1 inhibitors screening for glioma
by: Hui Li, et al.
Published: (2022-08-01)

Dual Inhibitors of PARPs and ROCKs
by: Albert A. Antolín, et al.
Published: (2018-10-01)

Comprehensive machine learning boosts structure-based virtual screening for PARP1 inhibitors
by: Klaudia Caba, et al.
Published: (2024-04-01)

Serine-linked PARP1 auto-modification controls PARP inhibitor response.
by: Prokhorova, E, et al.
Published: (2021)

Serine-linked PARP1 auto-modification controls PARP inhibitor response
by: Evgeniia Prokhorova, et al.
Published: (2021-07-01)

PARP inhibitors in cancer diagnosis and therapy
by: Chan, C, et al.
Published: (2020)

PARP Inhibitors Resistance: Mechanisms and Perspectives
by: Elena Giudice, et al.
Published: (2022-03-01)

PARP Inhibitors in Breast and Ovarian Cancer
by: Samuel S. Y. Wang, et al.
Published: (2023-04-01)

Advances in PARP Inhibitors for Prostate Cancer
by: Steven Tisseverasinghe, et al.
Published: (2023-03-01)

PARP inhibitors in metastatic prostate cancer
by: Amy K. Taylor, et al.
Published: (2023-04-01)

In vivo visualization of PARP inhibitor pharmacodynamics
by: Elizabeth S. McDonald, et al.
Published: (2021-04-01)

Resistance to PARP-inhibitors in Cancer Therapy
by: Alicia eMontoni, et al.
Published: (2013-02-01)

PARP Inhibitors in Prostate and Urothelial Cancers
by: Rohan Garje, et al.
Published: (2020-02-01)

In vitro analysis of PARP inhibitor nanoformulations
by: Baldwin P, et al.
Published: (2018-03-01)

PARPs, PAR and NAD Metabolism and Their Inhibitors in Cancer
by: Nicola Curtin, et al.
Published: (2020-11-01)

Combinations of PARP inhibitors with temozolomide drive PARP1 trapping and apoptosis in Ewing’s sarcoma
by: Gill, S, et al.
Published: (2015)

Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling
by: Hannah L. Smith, et al.
Published: (2022-11-01)

PARP1-SNAI2 transcription axis drives resistance to PARP inhibitor, Talazoparib
by: Xia Ding, et al.
Published: (2022-07-01)

PARP1pred: a web server for screening the bioactivity of inhibitors against DNA repair enzyme PARP-1
by: Tassanee Lerksuthirat, et al.
Published: (2023-01-01)

Successes and challenges of PARP inhibitors in cancer therapy
by: Tiffany K Ricks, et al.
Published: (2015-10-01)

Revealing the selective mechanisms of inhibitors to PARP-1 and PARP-2 via multiple computational methods
by: Hongye Hu, et al.
Published: (2020-05-01)

HMGB3 promotes PARP inhibitor resistance through interacting with PARP1 in ovarian cancer
by: Hanlin Ma, et al.
Published: (2022-03-01)

Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
by: Hyoung Kim, et al.
Published: (2020-07-01)

The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency
by: Marco Gatti, et al.
Published: (2020-08-01)

Development of PARP inhibitors in advanced prostate cancer
by: Maria Teresa Bourlon, et al.
Published: (2024-01-01)

PARP Inhibitors in Melanoma—An Expanding Therapeutic Option?
by: Wei Yen Chan, et al.
Published: (2021-09-01)

PARP Inhibitors and Haematological Malignancies—Friend or Foe?
by: Kathryn A. Skelding, et al.
Published: (2021-10-01)

PARP Inhibitors in Combination with Radiotherapy: To Do or Not to Do?
by: Amelia Barcellini, et al.
Published: (2021-10-01)

Advancements and Obstacles of PARP Inhibitors in Gastric Cancer
by: Hongjie Chen, et al.
Published: (2023-10-01)

Assessment of the PARP inhibitor talazoparib photosafety profile
by: Alejandro Mateos-Pujante, et al.
Published: (2023-11-01)

PARP Inhibitors and Proteins Interacting with SLX4
by: Lars Petter Jordheim
Published: (2023-02-01)

PARP inhibitors combined with radiotherapy: are we ready?
by: Chen Sun, et al.
Published: (2023-10-01)

PARP INHIBITORS IN OVARIAN CANCER: TOXICITY PROFILE
by: S. V. KHOKHLOVA, et al.
Published: (2017-06-01)

Sensitizing HR-proficient cancers to PARP inhibitors
by: Elgene Lim, et al.
Published: (2017-11-01)

PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
by: Ahrum Min, et al.
Published: (2020-02-01)

PARP Inhibitors in Ovarian Cancer: The Route to “Ithaca”
by: Stergios Boussios, et al.
Published: (2019-05-01)

Advances in using PARP inhibitors to treat cancer
by: Kummar Shivaani, et al.
Published: (2012-03-01)

PARP inhibitors in gastric cancer: beacon of hope
by: Yali Wang, et al.
Published: (2021-06-01)